Dan Gabriel Duda - Selected Publications#

As of January 2023, Thomson-Reuters H-index: 74 (23,000+ citations) and Google Scholar H-index: 86 (34,000+ citations); total number of publications: 260; Original articles: 158. Major recent publications:

1. Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. CXCR4 inhibition in tumour microenvironment facilitates anti-programmed death receptor 1 immunotherapy in sorafenib-treated HCC in mice. Hepatology 2015; 61: 1591-602.

Current IF: 17.3. Cited 295 times as of January 9, 2023; highly cited paper – top 1% of the academic field (Thomson-Reuters).

2. Hong TS, Grassberger C, Yeap B, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler C, Popescu I, DeLaney TF, Zhu AX, Duda DG. Pretreatment plasma hepatocyte growth factor as biomarker for susceptibility to radiation-induced liver dysfunction in liver cancer patients treated with radiotherapy. NPJ Precision Oncology 2018; 2: 22.

This study led to plasma HGF being validated as an integrated biomarker in a randomized phase III trial (NCT03186898), with funding support through an US DOD Impact Award (PI, Duda).

3. Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumour immune responses in HCC. Hepatology 2020; 71: 1247-61.

Current IF: 17.3. Cited 149 times as of January 9, 2023; highly cited paper – top 1% of the academic field (Thomson-Reuters). This combination therapy is currently developed for early intervention (in neoadjuvant setting for HCC) in a collaborative clinical study funded through NCI Award R01CA260872 (2021-2026) (PI, Duda).

4. Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier M, Chen I, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Quass A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG. Regorafenib increases T-cell infiltration when combined with PD1 blockade by inducing CXCL10 expression in HCC in mice. Journal of ImmunoTherapy for Cancer 2020; 8(2): e001435.

Current IF: 12.4. Cited 42 times as of January 9, 2023. Top 5% of all research outputs scored by Altmetric.

5. Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma. JAMA Oncology 2021; 7: 113-23.

Current IF: 31.7. Cited 116 times as of January 9, 2023; highly cited paper – top 1% of the academic field (Thomson-Reuters).

6. Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Kawakubo K, Tavakoli Nia H, Chen I, Sassi S, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TCE, Iwasaki M, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Jain RK, Zhu AX, Duda DG. Placental growth factor increases tumour invasion and desmoplasia in intrahepatic cholangiocarcinoma and promotes treatment-resistance. Gut 2022; 71: 185-93.

Current IF: 31.8. Top 5% of all research outputs scored by Altmetric.

7. Xiao Y, Chen J, Zhou H, Zeng X, Ruan R, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, Chen DS, Han X, Duda DG*, Shi J*. Combining CXCR4-Targeted p53 mRNA Nanotherapy with Immune Checkpoint Blockade Reprograms the Immune Microenvironment for Effective Immunotherapy in p53-null Liver Cancer. Nature Communications 2022; 13(1): 758.

Current IF: 14.9 (Thomson-Reuters). *Joint senior authors. Top 2% of all research outputs scored by Altmetric.

8. Kikuchi H, Matsui A, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Morita S, Huang P, Yau T, Jain RK, Duda DG. Increased CD8+ T-cell infiltration and efficacy for multikinase inhibitors after PD-1 blockade in HCC. Journal of the National Cancer Institute 2022; 114(9): 1301-1305.

Current IF: 13.5 (Thomson-Reuters). Top 5% of all research outputs scored by Altmetric.

9. IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases. 1st Edition; Springer-Nature. Editors: M. Makuuchi, N. Kokudo, I. Popescu, J. Belghiti, H.-S. Han, K. Takaori, and D. G. Duda. ePub on June 4, 2022 as doi: 10.1007/978-981-19-0063-1.

10. Chen S, Huang C, Liao G, Sun H, Xie Y, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Zeng Q, Zhang G, Liao C, Xie W, Shen S, Li S, Peng S, Kuang D, Zhao Q*, Duda DG*, Kuang M*. Distinct Single-cell Immune Ecosystems Distinguish True and De Novo HBV-related Hepatocellular Carcinoma Recurrences. Gut 2023; ePub on January 3, 2023 as doi: 10. 1136/ gutjnl-2022-328428.

Current IF: 31.8. *Co-Senior authors.